



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Martin MACPHEE *et al.*

Appl. No.: 08/474,086

Filed: June 7, 1995

For: SUPPLEMENTED AND UNSUPPLEMENTED  
TISSUE SEALANTS, METHODS OF THEIR  
PRODUCTION AND USE

Art Unit: 1643

Examiner: M. Zeman

Atty Docket: 1327.044000C

AS FILED 12/16/2002

**Declaration Under 37 C.F.R. § 1.132**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

I, the undersigned, Stanley A. Friedman, declare and state that:

1. My education and professional experience are set forth on the attached copy of my résumé (Exhibit A).

2. I have read and understand the specification and claims of United States Patent Application No. 08/474,086, filed June 7, 1995 in the name of Martin MacPhee *et al.* for SUPPLEMENTED AND UNSUPPLEMENTED TISSUE SEALANTS, METHODS OF THEIR PRODUCTION AND USE.

3. As stated on my résumé, as a part of my responsibilities at the American Red Cross, I have been involved in the development of fibrin sealant matrices as a delivery system for drugs and/or biologics.

4. On July 28, 1998, I attended an interview with Examiner Zeman and Supervisory Patent Examiner Knode at the United States Patent & Trademark Office. At that

**BEST AVAILABLE COPY**

interview, Dr. Martin MacPhee, one of the inventors named in the above-identified patent application, discussed the delivery kinetics of supplemented fibrin sealant matrices.

5. In conjunction with the discussion presented by Dr. MacPhee, a series of slides were displayed at the interview. A copy of each of the slides in the series that was displayed at the interview is attached to this Declaration (Exhibit B).

Below each slide is my brief description of the content thereof and its relevance to the delivery kinetics of supplemented fibrin sealant matrices.

6. I declare further that all statements made on information and belief are believed to be true, and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and such willful false statements may jeopardize the validity of the instant patent specification or any patent issuing thereon.

Respectfully submitted,



Dr. Stanley A. Friedman

Date:

P:\USERS\DMCPHAIL\ARC\044\friedman.132  
SKGF Rev. 1/28/98 dcw

## **RESUME**

**STANLEY A. FRIEDMAN, Ph.D.**

**Work address:**

Plasma Derivatives  
American Red Cross  
15601 Crabbs Branch Way  
Rockville, MD 20855  
(301) 738-0783  
(301) 738-0708 FAX

**Home address:**

4317 Regalwood Terrace  
Burtonsville, MD 20866  
(301) 549-1572

DOB: 7/28/54

## **EDUCATION**

**Doctor of Philosophy - Chemistry**  
University of California, San Diego  
September 1976 - August 1981

**Master of Science - Computer Science**  
Johns Hopkins University  
September 1985 - July 1987

**Bachelor of Arts - Chemistry**  
University of Maryland, Baltimore County  
September 1972 - June 1976

## **BACKGROUND**

**Scientist I**

Plasma Derivatives Department  
American Red Cross  
15601 Crabbs Branch Way  
Rockville, MD 20855  
October 1996 - present

Fibrin sealant forms a natural polymer matrix that makes an excellent local drug delivery system for drugs and/or biologics. My responsibilities were the development of research proposals, business plans, budgets, timelines and patents for novel uses for fibrin sealant.

Member of American Red Cross Task Force for implimentation of FDA regulations.

## STANLEY A. FRIEDMAN, Ph.D.

### Research Fellow

Department of Molecular Biology  
American Red Cross  
15601 Crabbs Branch Way  
Rockville, MD 20855  
Research Director - Dr. Tom Maciag  
October 1990 - November 1995

Fibroblast Growth Factor (FGF) is a mitogen for cell type derived from mesodermal and neuroectodermal origins. Various *in vitro* and *in vivo* studies were performed to determine the mechanism of FGF action. These studies include the construction of FGF and FGF receptor vectors for the *in vitro* expression of these genes to elicit the secretion mechanism and signal transduction pathways of mitogenic activity and the *in vivo* expression of FGF to study the mechanism of angiogenesis. *In vivo* transfection studies to determine if a dominant-negative FGF receptor inhibits the repair processes after a balloon angioplasty.

### Scientist II

Genetic Therapy, Inc.  
19 Firstfield Road  
Gaithersburg, Maryland  
January 1989 - September 1990

### Grant Awards

Small Business Innovation Research Program - Phase I - \$45,023  
Title - Retroviral Vectors to Express -Interferon in Human TIL

A variety of cytokine constructions were made in retroviral backgrounds for expression in humans. These retroviral particles were used to infect Tumor Infiltrating Lymphocytes (TIL) cells to enhance the TIL cells cancer fighting abilities.

### Scientist Associate

Laboratory of Chromosome Biology  
National Cancer Institute -  
Frederick Cancer Research Facility  
Frederick, Maryland  
June 1984 - December 1988  
Research Director - Dr. Stuart Austin

The chromosome partition of the unit-copy plasmid of the bacteriophage P1 to daughter cells of *E. coli* was investigated by cloning the partition region of P1 into the vector pBR322. Partition defective mutations were constructed *in vitro* in these clones. *E. coli* host mutations were also isolated and are presently being characterized. Other studies examined the regulation of the P1 partition operon by constructing protein and operon fusions to --galactosidase. Regulation defective mutations were isolated and characterized by DNA sequencing.

**STANLEY A. FRIEDMAN, Ph.D.**

**Postdoctoral Fellow**

Chemistry Department

University of Maryland, Baltimore County

September 1981 - May 1984

Research Director - Dr. John Hays

The effects of the Gam gene product on E. coli was investigated by cloning gam. The Gam gene product was found to specifically inhibit the nuclease activity of recBC in vivo and in vitro. RecBC mediated recombination, which was measured by Hfr mating, P1 transduction and Chi crosses, was not inhibited by gam.

**Graduate research Assistant**

Chemistry Department

University of California, San Diego

September, 1976 - August, 1981

Research Director - Dr. John Leong

The mode of action of the transition metal chelating antibiotic, thioformin was investigated. The transition metals were found to stimulate cellular uptake of radioactively labeled thioformin. Attempts were made to determine the target of the antibiotic by measuring in vivo inhibition of cellular processes in the presence of the antibiotic. Some of the processes examined were ATP, ppGpp and pppGpp levels, O<sub>2</sub> consumption, and the synthesis of DNA, RNA, and proteins. The antibiotic induced a shift-down by effecting energy production.

**Undergraduate Research Assistant**

Chemistry Department

University of Maryland, Baltimore County

December, 1974 - August, 1976

The membrane bound sugar transport system of Staphylococcus aureus was examined by purification and characterization of the enzymes involved in the process. In vivo and in vitro enzyme kinetic studies were performed.

Supervision and training of a graduate student

## STANLEY A. FRIEDMAN, Ph.D.

### PUBLICATIONS

1. Friedman, S.A. and J.B. Hays. 1977. Initial characterization of hexose and hexitol phosphoenolpyruvate-dependent phosphotransferases of *Staphylococcus aureus*. J. Bacteriol. 130:991.
2. Friedman, S.A., R.M. Cooper, and J.B. Hays. 1977. The same reversible aggregating soluble protein is required for PEP-dependent phosphorylation of mannitol and sorbitol in *Staphylococcus aureus*. FEMS.1:311.
3. Bell, S.J., S.A. Friedman, and J. Leong. 1979. Antibiotic action of N-methylthioformohydroxamate metal complexes. Antimicrob. Agents Chemother. 15:387.
4. Hays, J.B., T.A.G. Smith, S.A. Friedman, E. Lee, and G.L. Coffman. 1984. RecF and RecBC functions during recombination of non-replicating, UV-irradiated phage DNA and during other recombination processes. Cold Spring Harbor Symp. Quant. Biol. 49:475-483.
5. Abeles, A.L., S.A. Friedman, and S.J. Austin. 1985. Partition of unit-copy miniplasmids to daughter cells III. The DNA sequence and functional organization of the P1 partition region. J. Mol. Biol. 85:261-272.
6. Friedman, S.A., and J.B. Hays. 1986. Selective inhibition of *Escherichia coli* RecBC enzyme functions by plasmid-encoded phage Gam activity. Gene. 43:255.
7. Austin, S., S. Friedman, and D. Ludtke. 1986. The partition functions of three unit-copy plasmids can stabilize the maintenance of plasmid pBR322 at low copy number. J. Bacteriol. 168:1010-1013.
8. Friedman, S., K. Martin and S. Austin. 1986. The partition system of the P1 plasmid. In: Banbury Report 24: Antibiotic Resistance Genes: Ecology, Transfer, and Expression (S.B. Levy and R.P. Novick, eds.). Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 285-295.
9. Martin, K.A., S.A. Friedman, and S.J. Austin. 1987. The partition site of the P1 plasmid. Proc. Natl. Acad. Sci., USA. 84:8544-8547.
10. Friedman, S.A., and S.J. Austin. 1988. The P1 plasmid-partition system synthesizes two essential proteins from an autoregulated operon. Plasmid 19:103-112.
11. Zhan, X., X. Hu, S. Friedman, and T. Maciag. 1992. Analysis of Endogenous and Exogenous Nuclear Translocation of Fibroblast Growth Factor-1 in NIH 3T3 Cells. Biochem. Biophys. Res. Comm. 188:982-991.
12. Jackson, A., S. Friedman, X. Zhan, K.A. Engleka, R. Forough, and T. Maciag. 1992. Heat shock induces the release of fibroblast growth factor 1 from NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 89:10691-10695.
13. Forough, R., X. Zhan, M. MacPhee, S. Friedman, K.A. Engleka, T. Sayers, R.H. Wilttrout, and T. Maciag. 1993. Differential Transforming Abilities of Non-secreted and Secreted Forms of Human Fibroblast Growth Factor-1. J. Biol. Chem. 268:2960-2968.
14. Friedman, S., X. Zhan, and T. Maciag. 1994. Mutagenesis of the Nuclear Translocation Sequence in FGF-1 Alters Protein Stability But Not Mitogenic Activity. Biochem. Biophys. Res. Comm. 198:1203-1208.
15. Maciag, T., X. Zhan, S. Friedman, S. Garfinkel, I. Prudovsky, A. Jackson, J. Wessendorf, X. Hu, S. Gamble, J. Shi, S. Brown, F. Tarantini, and A. Zimrin. 1994. Novel Mechanisms of Fibroblast Growth Factor-1 Function. Prog. Hormone Res. 49:105-123.

**STANLEY A. FRIEDMAN, Ph.D.**

16. Jackson, A., F. Tarantini, S. Gamble, S. Friedman, and T. Maciag. 1995. The Release of Fibroblast Growth Factor-1 from NIH 3T3 Cells in Response to Temperature Involves the Function of Cysteine Residues. *J. Biol. Chem.* 270:33-36.
17. Imamura, T., S. Friedman, S. Gamble, Y. Tokita, S.R. Opalenik, J.A. Thompson, and T. Maciag. 1995. Identification of the Domain Within Fibroblast Growth Factor-1 Responsible for Heparin-dependence. *Biochim. Biophys. Acta* 1266:124-130.
18. Finch, P.W., L.K. Yee, M.Y.W. Chu, T.M. Chen, M.H. Lipsky, T. Maciag, S. Friedman, M.H. Epstein, and P. Calabresi. 1997. Inhibition of Growth Factor Mitogenicity and Growth of Tumor Cell Xenografts by a Sulfonated Distamycin A Derivative. *Pharmacology* 55:269-278.
19. Shi, J., S. Friedman, and T. Maciag. 1997. A Carboxyl-Terminal Domain in Fibroblast Growth Factor (FGF)-2 Inhibits FGF-1 Release In Response to Heat Shock *In Vitro*. *J. Biol. Chem.* 272:1142-1147.
20. Jackson, M.R., S.A. Friedman, A.J. Carter, V. Bayer, J.R. Burge, M.J. MacPhee, W.N. Drohan, and B.M. Alving. 1997. Hemostatic Efficacy of a Fibrin-based Topical Agent in a Femoral Artery Injury Model: A Randomized, Blinded, Placebo-controlled Study. *J. Vas. Surg.* 26:274-280.

**Patents**

MacPhee, M., W.N. Drohan, D. Beall, S. Friedman, D. Tuthill, and V. Bayer. 1998. Hemostatic Sandwich Bandage. Patent Pending

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.